Merging the Histologic and Molecular Data Into an Integrated Score Significantly Improves Precision in Stratification of Meningiomas
Integrated molecular-morphologic meningiomas classification by the German Consortium on Aggressive Meningiomas
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1644 results
FDA Recognises OncoKB Database of Molecular Tumour Marker Information
A portion of the OncoKB is recognised as a source of valid scientific evidence for Level 2 and Level 3 biomarkers
FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia
Evidence for efficacy is based on the results from the ZUMA-3 study
Adjuvant Chemotherapy Customisation Based on ERCC1 and TS mRNA Levels Does Not Improve Efficacy in Resected NSCLC
Findings from the ITACA study in patients with completely resected, stage II-IIIA non-small cell lung cancer
EMA Recommends Granting a Marketing Authorisation for Ripretinib for the Treatment of Advanced GIST
It is indicated for the treatment of adult patients who have received prior treatment with three or more kinase inhibitors, including imatinib
Abiraterone Acetate Plus Prednisone and LHRH Analogue is Active and Safe in AR-Expressing, Castration-Resistant Salivary Gland Carcinoma
Findings from a phase II study in second-line treatment
EMA Recommends Extension of Therapeutic Indications for Nivolumab
New indication concerns the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, GEJ or oesophageal adenocarcinoma
Patients Treated With Chemotherapy and B Cell–Targeting Agents Show Impaired Serological Response to COVID-19 Vaccination
Findings from the largest study to measure anti-SARS-CoV-2 antibody levels after vaccination in patients with haematological and solid malignant tumours
FDA Approves Cabozantinib for Differentiated Thyroid Cancer
Evidence for efficacy is based on the results from the COSMIC-311 study
Poziotinib Shows Promising Antitumour Activity in Patients with HER2 Exon 20 Mutated NSCLC
Findings from a phase II single-arm investigator-initiated study
EMA Recommends Granting a Conditional Marketing Authorisation for Pralsetinib
It is intended for the treatment of patients with RET fusion positive NSCLC
Treatment with Tebentafusp Results in Longer Overall Survival Among Previously Untreated Patients with Metastatic Uveal Melanoma
Findings from the IMCgp100-202 study